Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | CA7 | P43166 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10784953 | 0.90 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7534896 | 0.87 | CA1 (0.79) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL8489 | 0.83 | CA1 (1.00) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL21802643 | 0.83 | CA1 (1.00) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7534892 | 0.81 | CA1 (0.69) | CA1CA2CA7CA9CA12 | |
| SCHEMBL14224220 | 0.79 | ACHE (0.60) | CA1CA2CA7CA9CA12 | |
| SCHEMBL24462099 | 0.77 | TDP1 (0.62) | ACHETDP1MAPK1ALDH1A1KDM4E | |
| SCHEMBL7781869 | 0.77 | LTA4H (0.54) | CA1CA2CA7CA9CA12 | |
| SCHEMBL24209436 | 0.77 | NFE2L2 (0.48) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL11373286 | 0.76 | CA1 (0.85) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334099-B2 | Nucleic acid amplification using a reversibly modified oligonucleotide | BI WANLI (US) | 2012-12-18 | — | — | US | claimed |
| EP-2049689-B1 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | BI WANLI (US) | 2011-12-21 | — | — | EP | claimed |
| CN-101812060-B | Simple novel method for preparing high-purity Sprycel, and intermediate compound | NANJING CAVENDISH BIOENGINEERING TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | claimed |
| US-20100021970-A1 | Nucleic Acid Amplification Using a Reversibly Modified Oligonucleotide | BI WANLI | 2010-01-28 | — | — | US | claimed |
| EP-2049689-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | Bi, Wanli (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008016562-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | BI WANLI (US) | 2008-02-07 | — | — | WO | claimed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | AGENSYS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-111330016-B | Antibody Drug Conjugates (ADCs) that bind 158P1D7 protein | 艾更斯司股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-1896480-A1 | CRIPOWELLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | Bayer CropScience Aktiengesellschaft (DE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2008019784-A2 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008016562-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | BI WANLI (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2006136309-A1 | CRIPOWELLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1412346-B1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2005-03-09 | — | — | EP | disclosed |
| EP-1412346-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | Bayer CropScience AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003010155-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | CA1 2949/4885CA2 3022/4885CA7 1946/4885 |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, CA12, H1-10 | CA1 39/4885CA2 256/4885CA7 389/4885 |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | TMED10, CD44, CA12 | CA1 233/4885CA2 822/4885CA7 533/4885 |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, ARID2, DYNLL2 | CA1 2484/4885CA2 3031/4885CA7 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.